Association between genomic instability score and progression-free/overall survival in patients with newly diagnosed non-BRCA1/2 ovarian cancer

We sought to describe the association between genomic instability score (GIS) and progression-free survival (PFS) and overall survival (OS) in patients with newly diagnosed, non-BRCA1/2 ovarian cancer. Homologous recombinant deficiency (HRD) status was based on a cutoff of ≥42 GIS; patients

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Gynecologic oncology 2024-12, Vol.192, p.120-127
Hauptverfasser:	Graves, Stephen, Sullivan, Mackenzie W., Adkoli, Anusha, Zhou, Qin, Iasonos, Alexia, Selenica, Pier, Aghajanian, Carol, Liu, Ying L., Tew, William, Sonoda, Yukio, Ellenson, Lora H., Chi, Dennis, O'Cearbhaill, Roisin E., Weigelt, Britta, Grisham, Rachel N.
Format:	Artikel
Sprache:	eng
Schlagworte:	BRCA-negative homologous recombination deficiency outcomes Homologous recombination deficiency testing Maintenance therapy Ovarian cancer Overall survival PARP inhibitor
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	We sought to describe the association between genomic instability score (GIS) and progression-free survival (PFS) and overall survival (OS) in patients with newly diagnosed, non-BRCA1/2 ovarian cancer. Homologous recombinant deficiency (HRD) status was based on a cutoff of ≥42 GIS; patients
ISSN:	0090-8258 1095-6859 1095-6859
DOI:	10.1016/j.ygyno.2024.11.011